novo nordisk semaglutide shortage The Is Ending: What's Next For Compounded Drugs? Novo Nordisk faces 'must-win' battle

About 60% were men, and the median age was 53 years

A study at Penn Medicine, funded by Novo Nordisk, found that participants taking semaglutide lost an average of 16% of their starting weight and more than one-third lost 20% or more of their baseline weight during the 68-week study

Or they may simply feel different from what the person is used to

Diagnostic tests, including ultrasound imaging of the gallbladder and liver function tests, can help determine the cause of the symptoms and guide appropriate treatment

Many patients complement their weight loss program with treatments like B12 injections for energy support, NAD+ injections for cellular health, or CoolSculpting for targeted body contouring once they've reached or neared their goal weight